LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 6 of 15: Mean cell count and mean growth rate across biological replicate 3. - Dataset (ID:20242)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | PI103 | 0.12 | uM | LJP6 | 72 | hr | 1401 | 2604 | 4223 | 0.6167 | 0.4263 |
| SK-BR-3 | PLX-4720 | 0.12 | uM | LJP5 | 72 | hr | 1401 | 4352 | 4223 | 1.0305 | 1.0457 |
| SK-BR-3 | QL-X-138 | 0.12 | uM | LJP6 | 72 | hr | 1401 | 2765 | 4223 | 0.6549 | 0.4835 |
| SK-BR-3 | QL-XII-47 | 0.12 | uM | LJP6 | 72 | hr | 1401 | 2306 | 4223 | 0.5461 | 0.3206 |
| SK-BR-3 | Radicicol | 0.12 | uM | LJP5 | 72 | hr | 1401 | 1780 | 4223 | 0.4215 | 0.1341 |
| SK-BR-3 | Radicicol | 0.12 | uM | LJP6 | 72 | hr | 1401 | 1639 | 4223 | 0.3883 | 0.0844 |
| SK-BR-3 | Seliciclib | 0.12 | uM | LJP5 | 72 | hr | 1401 | 4234 | 4223 | 1.0027 | 1.0041 |
| SK-BR-3 | Ruxolitinib | 0.12 | uM | LJP5 | 72 | hr | 1401 | 4244 | 4223 | 1.0050 | 1.0075 |
| SK-BR-3 | XL147 | 0.12 | uM | LJP5 | 72 | hr | 1401 | 4821 | 4223 | 1.1417 | 1.2121 |
| SK-BR-3 | Saracatinib | 0.12 | uM | LJP6 | 72 | hr | 1401 | 4520 | 4223 | 1.0703 | 1.1052 |
| SK-BR-3 | Selumetinib | 0.12 | uM | LJP6 | 72 | hr | 1401 | 4317 | 4223 | 1.0222 | 1.0333 |
| SK-BR-3 | Sirolimus | 0.12 | uM | LJP6 | 72 | hr | 1401 | 2685 | 4223 | 0.6360 | 0.4551 |
| SK-BR-3 | Sorafenib | 0.12 | uM | LJP6 | 72 | hr | 1401 | 4043 | 4223 | 0.9574 | 0.9362 |
| SK-BR-3 | SU11274 | 0.12 | uM | LJP5 | 72 | hr | 1401 | 4255 | 4223 | 1.0076 | 1.0114 |
| SK-BR-3 | Fedratinib | 0.12 | uM | LJP5 | 72 | hr | 1401 | 4226 | 4223 | 1.0008 | 1.0011 |
| SK-BR-3 | TGX221 | 0.12 | uM | LJP5 | 72 | hr | 1401 | 3744 | 4223 | 0.8867 | 0.8304 |
| SK-BR-3 | Torin1 | 0.12 | uM | LJP6 | 72 | hr | 1401 | 1724 | 4223 | 0.4083 | 0.1144 |
| SK-BR-3 | Torin2 | 0.12 | uM | LJP5 | 72 | hr | 1401 | 1310 | 4223 | 0.3102 | -0.0324 |
| SK-BR-3 | Tozasertib | 0.12 | uM | LJP5 | 72 | hr | 1401 | 1312 | 4223 | 0.3108 | -0.0315 |
| SK-BR-3 | Trametinib | 0.12 | uM | LJP5 | 72 | hr | 1401 | 3265 | 4223 | 0.7732 | 0.6606 |
| SK-BR-3 | TWS119 | 0.12 | uM | LJP5 | 72 | hr | 1401 | 4472 | 4223 | 1.0590 | 1.0883 |
| SK-BR-3 | Vemurafenib | 0.12 | uM | LJP5 | 72 | hr | 1401 | 4341 | 4223 | 1.0280 | 1.0419 |
| SK-BR-3 | Withaferin A | 0.12 | uM | LJP5 | 72 | hr | 1401 | 4516 | 4223 | 1.0694 | 1.1039 |
| SK-BR-3 | Withaferin A | 0.12 | uM | LJP6 | 72 | hr | 1401 | 3721 | 4223 | 0.8813 | 0.8223 |
| SK-BR-3 | WYE-125132 | 0.12 | uM | LJP6 | 72 | hr | 1401 | 1649 | 4223 | 0.3905 | 0.0877 |